Cover Image
市場調查報告書

女性用避孕器:開發中產品分析

Female Contraception - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363113
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
Back to Top
女性用避孕器:開發中產品分析 Female Contraception - Pipeline Review, H2 2016
出版日期: 2016年12月30日 內容資訊: 英文 89 Pages
簡介

本報告提供女性用避孕器的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

女性用避孕器概要

女性用避孕器的開發

  • 開發中產品的概要
  • 開發中產品比較分析

女性用避孕器:企業開發中的治療藥

女性用避孕器:大學/機關研究中的治療藥

女性用避孕器:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

女性用避孕器:企業開發中的產品

女性用避孕器:大學/機關研究中的產品

女性用避孕器治療藥的開發企業

  • Agile Therapeutics, Inc.
  • ANI Pharmaceuticals, Inc.
  • Evofem, Inc.
  • Mithra Pharmaceuticals S.A.
  • Orbis Biosciences, Inc.

女性用避孕器:評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

簡介

女性用避孕器:暫停中的計劃

女性用避孕器:中止開發的產品

女性用避孕器:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8847IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H2 2016, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 5, 2, 6 and 5 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 2 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Female Contraception Overview
  • Therapeutics Development
    • Pipeline Products for Female Contraception - Overview
    • Pipeline Products for Female Contraception - Comparative Analysis
  • Female Contraception - Therapeutics under Development by Companies
  • Female Contraception - Therapeutics under Investigation by Universities/Institutes
  • Female Contraception - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Female Contraception - Products under Development by Companies
  • Female Contraception - Products under Investigation by Universities/Institutes
  • Female Contraception - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Agile Therapeutics Inc
    • ANI Pharmaceuticals Inc
    • Bayer AG
    • Evofem Inc
    • Hervana Ltd
    • Mithra Pharmaceuticals SA
    • Orbis Biosciences Inc
    • Teva Pharmaceutical Industries Ltd
    • Viramal Ltd
  • Female Contraception - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (anastrozole + levonorgestrel) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (drospirenone + estetrol) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (estradiol acetate + prasterone + progesterone) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (estradiol acetate + segesterone acetate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-68693 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-200 ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-200 SP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-20015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-890 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Amphora - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1007626 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • drospirenone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-508 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Estetrol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etonogestrel ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EVE-106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJ-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOV-1003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-003296 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-0101255 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 for Fertility Control - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Progesterone Receptor for Fertility Control - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Female Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TV-46046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Female Contraception - Dormant Projects
  • Female Contraception - Discontinued Products
  • Female Contraception - Product Development Milestones
    • Featured News & Press Releases
      • Nov 07, 2016: Agile Therapeutics Announces Completion of Subject Visits for Twirla Phase 3 SECURE Clinical Trial
      • Sep 23, 2016: Mithra Pharmaceuticals: Phase III Clinical Study for Estelle in US Launched with first Randomized Patient
      • Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68693
      • Jul 22, 2016: Green Light From FDA For The Launch Of Estelle (E4/Drsp) Phase III Study In The United States
      • Jul 20, 2016: Canada Approves Clinical Trial Application For Estelle (E4/DRSP) PhasePhase III Study
      • Jul 12, 2016: Agile Therapeutics Announces Plans to Advance Contraceptive Pipeline
      • Jun 30, 2016: First Patient Screened For The European Product Candidate Estelle (E4/Drsp) Phase III Clinical Study
      • Jun 16, 2016: Agile Therapeutics Announces Issuance of Patent for Progestin Patch Designs
      • Apr 05, 2016: FDA Feedback On Spa Estelle: A New Step Closer To The Launch Of Estelle Phase III Pivotal Clinical Studies
      • Apr 01, 2016: Topline Results Of Food Effect Study Of The Product Candidate Estelle, The New Combined Oral Contraceptive Composed Of 15 mg Of Estetrol (E4) And 3 mg Of Drospirenone
      • Mar 24, 2016: Already 4 European Countries Fully Approved Protocol Of MIT-ES001-C301 Estelle Phase III Clinical Study
      • Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial
      • Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial
      • Sep 22, 2015: Evofem Announces FDA Acceptance of New Drug Application for Amphora as a Contraceptive
      • Aug 31, 2015: Agile Therapeutics Announces Completion of Patient Recruitment in Twirla Phase 3 SECURE Clinical Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Female Contraception, H2 2016
  • Number of Products under Development for Female Contraception - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Female Contraception - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Female Contraception - Pipeline by Agile Therapeutics Inc, H2 2016
  • Female Contraception - Pipeline by ANI Pharmaceuticals Inc, H2 2016
  • Female Contraception - Pipeline by Bayer AG, H2 2016
  • Female Contraception - Pipeline by Evofem Inc, H2 2016
  • Female Contraception - Pipeline by Hervana Ltd, H2 2016
  • Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H2 2016
  • Female Contraception - Pipeline by Orbis Biosciences Inc, H2 2016
  • Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016
  • Female Contraception - Pipeline by Viramal Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Female Contraception - Dormant Projects, H2 2016
  • Female Contraception - Dormant Projects (Contd..1), H2 2016
  • Female Contraception - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Female Contraception, H2 2016
  • Number of Products under Development for Female Contraception - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top